Overview

Useful For
An aid in the differentiation of benign from malignant melanocytic lesions when used in conjunction with clinical and pathologic information

Reflex Tests

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Reporting Name</th>
<th>Available Separately</th>
<th>Always Performed</th>
</tr>
</thead>
<tbody>
<tr>
<td>I099</td>
<td>Interphases, 25-99</td>
<td>No, (Bill Only)</td>
<td>No</td>
</tr>
<tr>
<td>I300</td>
<td>Interphases, &gt;=100</td>
<td>No, (Bill Only)</td>
<td>No</td>
</tr>
<tr>
<td>IL25</td>
<td>Interphases,</td>
<td>No, (Bill Only)</td>
<td>No</td>
</tr>
<tr>
<td>PADD</td>
<td>Probe, +1</td>
<td>No, (Bill Only)</td>
<td>No</td>
</tr>
<tr>
<td>PB02</td>
<td>Probe, +2</td>
<td>No, (Bill Only)</td>
<td>No</td>
</tr>
<tr>
<td>PB03</td>
<td>Probe, +3</td>
<td>No, (Bill Only)</td>
<td>No</td>
</tr>
<tr>
<td>PBCT</td>
<td>Probe, +2</td>
<td>No, (Bill Only)</td>
<td>No</td>
</tr>
</tbody>
</table>

Testing Algorithm
This test does not include a pathology consult. If a pathology consultation is requested, PATHC / Pathology Consultation should be ordered and the appropriate FISH test will be ordered and performed at an additional charge.

This test includes a charge for application of the first probe set (2 FISH probes) and professional interpretation of results.

Additional charges will be incurred for all reflex probes performed. Analysis charges will be incurred based on the number of cells analyzed per probe set. If no cells are available for analysis, no analysis charges will be incurred.

Method Name
Fluorescence In Situ Hybridization (FISH)

NY State Available
Yes

Specimen

Specimen Type
Tissue

Shipping Instructions
Advise Express Mail or equivalent if not on courier service.

Necessary Information
Provide a reason for referral and pathology report with each specimen. The laboratory will not reject testing if this information is not provided, but appropriate testing and interpretation may be compromised or delayed.
Specimen Required
Submit only 1 of the following specimens:

Specimen Type: Tissue

Preferred: Tissue block

Collection Instructions: Submit a formalin-fixed, paraffin-embedded (FFPE) tumor tissue block. Blocks prepared with alternative fixation methods may be acceptable; provide fixation method used.

Acceptable: Slides

Collection Instructions: Seven consecutive, unstained, 5 micron-thick sections placed on positively charged slides, and 1 hematoxylin and eosin (H and E) stained slide.

Forms
If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.

Specimen Minimum Volume
Three consecutive, unstained, 5 micron-thick sections placed on positively charged slides and 1 (H&E) stained slide

Reject Due To
Note: No specimen should be rejected. If specimen not received at appropriate temperature or in wrong anticoagulant, include note to laboratory. If questions, contact laboratory.

Specimen Stability Information

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Temperature</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tissue</td>
<td>Ambivalent (preferred)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Refrigerated</td>
<td></td>
</tr>
</tbody>
</table>

Clinical and Interpetive

Clinical Information

Melanocytic tumors arising in the skin can present a significant diagnostic challenge. While many lesions can be easily classified as benign nevi or malignant melanoma based on histologic features alone, there is a significant subset of lesions that cannot be clearly defined as either benign or malignant. Because the course of treatment for malignant melanoma relative to benign lesions varies significantly from the time of diagnosis, accuracy, and expediency of the diagnosis are of paramount importance. A FISH-based test panel has been developed that can be used as a diagnostic aid in the differentiation of malignant from benign melanocytic lesions.

This test is intended to be used in conjunction with clinical and pathologic information to aid the pathologist in the differentiation of benign from malignant melanocytic lesions.
Reference Values
An interpretive report will be provided.

Interpretation
The panel test is considered abnormal if certain parameters are met that have been shown to be observed in malignant melanocytic lesions and within normal limits if these parameters are not met.

An abnormal result is not diagnostic of malignancy, nor does a normal result exclude malignancy.

The results are intended to be interpreted in the context of the pathologic and clinical findings.

Cautions
This test is not approved by the US Food and Drug Administration and it is best used as an adjunct to existing clinical and pathologic information.

Fixatives other than formalin (eg, Prefer, Bouin) may not be successful for FISH assays. Although FISH testing will not be rejected due to non-formalin fixation, results may be compromised.

Paraffin-embedded tissues that have been decalcified are generally unsuccessful for FISH analysis. The pathologist reviewing the hematoxylin and eosin-stained slide may find it necessary to cancel testing.

Supportive Data
FISH analysis was performed on 55 formalin-fixed, paraffin-embedded tissue samples, including 29 samples from patients suspected or diagnosed with melanoma and 26 histologically nonmalignant nevi (normal). The normal controls were used to generate a normal cutoff for this assay. Of the 29 suspected or diagnosed cases with melanoma, 26 were abnormal for at least 1 of the probes tested and at least 50% of the nuclei exhibited the abnormality. Three cases were considered equivocal since the abnormality was identified in <50% of nuclei.

Clinical Reference
Performance

Method Description
This test is performed using 3 commercially available enumeration strategy probes sets: a) RREB1/D6Z1/ MYB/CCND1, b) CDKN2A/D9Z1, and c) D8Z2/MYC. Formalin-fixed, paraffin-embedded tissues are cut at 5 microns and mounted on positively charged glass slides. The selection of tissue and the identification of target areas on the hematoxylin and eosin (H and E)-stained slide are performed by a pathologist. Using the H and E-stained slide as a reference, target areas are etched with a diamond-tipped etcher on the back of the unstained slide to be assayed. The probes are hybridized to the appropriate target areas and 2 technologists each analyze 25 interphase nuclei each (50 cells total for each probe set) with the results expressed as the percent of abnormal nuclei.(Unpublished Mayo method)

PDF Report
No

Day(s) and Time(s) Test Performed
Samples processed Monday through Sunday. Results reported Monday through Friday, 8 a.m.-5 p.m. CST.

Analytic Time
7 days

Maximum Laboratory Time
10 days

Specimen Retention Time
Slides and H&E used for analysis are retained by the lab indefinitely. Client provided paraffin blocks and extra unstained slides (if provided) will be returned after testing is complete.

Performing Laboratory Location
Rochester

Fees and Codes

Fees
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information
88271x2, 88291 â€“ DNA probe, each (first probe set), Interpretation and report

88271x2 â€“ DNA probe, each; each additional probe set (if appropriate)

88271x1 â€“ DNA probe, each; coverage for sets containing 3 probes (if appropriate)
**Test Definition: MELF**  
Melanoma, FISH, Ts

88271x2 "DNA probe, each; coverage for sets containing 4 probes (if appropriate)"

88271x3 "DNA probe, each; coverage for sets containing 5 probes (if appropriate)"

88274 w/modifier 52 "Interphase in situ hybridization, <25 cells, each probe set (if appropriate)"

88274 "Interphase in situ hybridization, 25 to 99 cells, each probe set (if appropriate)"

88275 "Interphase in situ hybridization, 100 to 300 cells, each probe set (if appropriate)"

**LOINC® Information**

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Test Order Name</th>
<th>Order LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>MELF</td>
<td>Melanoma, FISH, Ts</td>
<td>In Process</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Result ID</th>
<th>Test Result Name</th>
<th>Result LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>52123</td>
<td>Result Summary</td>
<td>50397-9</td>
</tr>
<tr>
<td>52125</td>
<td>Interpretation</td>
<td>69965-2</td>
</tr>
<tr>
<td>52124</td>
<td>Result</td>
<td>62356-1</td>
</tr>
<tr>
<td>CG741</td>
<td>Reason for Referral</td>
<td>42349-1</td>
</tr>
<tr>
<td>52126</td>
<td>Specimen</td>
<td>31208-2</td>
</tr>
<tr>
<td>52127</td>
<td>Source</td>
<td>31208-2</td>
</tr>
<tr>
<td>52128</td>
<td>Tissue ID</td>
<td>80398-1</td>
</tr>
<tr>
<td>52129</td>
<td>Method</td>
<td>49549-9</td>
</tr>
<tr>
<td>54581</td>
<td>Additional Information</td>
<td>48767-8</td>
</tr>
<tr>
<td>53834</td>
<td>Disclaimer</td>
<td>62364-5</td>
</tr>
<tr>
<td>52130</td>
<td>Released By</td>
<td>18771-6</td>
</tr>
</tbody>
</table>